Results 11 to 20 of about 8,546 (246)

Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer's disease [PDF]

Nature Aging, 2021
The evident genetic, pathological, and clinical heterogeneity of Alzheimer’s disease (AD) poses challenges for traditional drug development. We conducted a computational drug repurposing screen for drugs to treat apolipoprotein (apo) E4-related AD.
Jones, Emily A. Aery, Hao, Yanxia, Jones, Aery, Huang, Yadong, Chang, William, William Chang, William, Yoon, Seo Yeon, Zalocusky, Kelly A, Choudhary, Krishna, Pineda, Silvia, Zalocusky, Kelly A., Paranjpe, Ishan, Oskotsky, Tomiko, Jones, Emily A Aery, Alice Taubes, Alice, Zilberter, Misha Y., Glicksberg, Benjamin S., Grone, Brian, De Freitas, Jessica, Balestra, Maureen E, Wang, Celine, Nova, Phil, An, Alice, Balestra, Maureen E., Chen, Bin, Grone, Brian, Taubes, Alice, Chen, Nuo, Koutsodendris, Nicole, Pineda Sanjuan, Silvia, Chaudhry, Fayzan, Kosti, Idit, Zilberter, Misha Y, Bin Chen, Emily A., Bicak, Mesude, Sirota, Marina, Glicksberg, Benjamin S   +36 more
core   +2 more sources

Bumetanide induces post-traumatic microglia-interneuron contact to promote neurogenesis and recovery. [PDF]

Brain : a journal of neurology, 2023
Although the Na-K-Cl cotransporter (NKCC1) inhibitor bumetanide has prominent positive effects on the pathophysiology of many neurological disorders, the mechanism of action is obscure.
Marine Tessier (17099638), Edith Blasco (17099641), Marta Saez Garcia (9302681), Emmanuelle Goubert (6295475), Claudio Rivera (5958458), Li Tian (207552), Florence Molinari (17099647), Benoit Dehapiot (11402618), François Guillemot (63742), Amandine Consumi (17099644), Jerome Laurin (17099650), Christophe Pellegrino (5958461), Christian A Hübner (17099653)   +12 more
core   +3 more sources

Structural basis for inhibition of the Cation-chloride cotransporter NKCC1 by the diuretic drug bumetanide

Nature Communications, 2022
Loop diuretics including bumetanide inhibit Na+-K+-Cl−-cotransporters (NKCCs) and are used for the treatment of edema and hypertension. Here, Zhao et. al.
Yongxiang Zhao, Kasturi Roy, Pietro Vidossich, Laura Cancedda, Marco De Vivo, Biff Forbush, Erhu Cao   +6 more
doaj   +2 more sources

A Wholistic View of How Bumetanide Attenuates Autism Spectrum Disorders

Cells, 2022
The specific NKCC1 cotransporter antagonist, bumetanide, attenuates the severity of Autism Spectrum Disorders (ASD), and many neurodevelopmental or neurodegenerative disorders in animal models and clinical trials.
Eric Delpire, Yehezkel Ben-Ari
doaj   +2 more sources

The GABA Polarity Shift and Bumetanide Treatment: Making Sense Requires Unbiased and Undogmatic Analysis

Cells, 2022
GABA depolarizes and often excites immature neurons in all animal species and brain structures investigated due to a developmentally regulated reduction in intracellular chloride concentration ([Cl−]i) levels.
Yehezkel Ben-Ari, Enrico Cherubini
doaj   +2 more sources

Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundDapagliflozin inhibits the sodium‐glucose–linked transporter 2 in the renal proximal tubule, thereby promoting glycosuria to reduce hyperglycemia in type 2 diabetes mellitus. Because these patients may require loop diuretics, and sodium‐glucose–
Christopher S. Wilcox, Wen Shen, David W. Boulton, Bruce R. Leslie, Steven C. Griffen   +4 more
doaj   +2 more sources

Bumetanide for autism: Open‐label trial in six children

Acta paediatrica, 2021
Aim: Bumetanide, a diuretic agent, that reduces intracellular chloride—thereby reinforcing GABAergic inhibition—has been reported to improve core symptoms of autism in children.
Peik Gustafsson, Elisabeth Fernell, Gillberg, Christopher, Fernell, Elisabeth, Christopher Gillberg, Gustafsson, Peik   +5 more
core   +2 more sources

Bumetanide for autism: more eye contact, less amygdala activation [PDF]

Scientific Reports, 2018
We recently showed that constraining eye contact leads to exaggerated increase of amygdala activation in autism. Here, in a proof of concept pilot study, we demonstrate that administration of bumetanide (a NKCC1 chloride importer antagonist that restores
Zürcher, N.R., Gillberg, Christopher, Gillberg, C., Johnels, J.A., Jakob Åsberg Johnels, Nicole R. Zürcher, Hadjikhani, Nouchine,, Åsberg Johnels, Jakob, Hadjikhani, N., Lassalle, A., Zürcher, Nicole R., Ben-Ari, Yehezkel, Yehezkel Ben-Ari, Loyse Hippolyte, Gillberg, Christopher,, Nouchine Hadjikhani, Lassalle, Amandine, Hadjikhani, Nouchine, Hippolyte, Loyse, Zürcher, N. R., Eric Lemonnier, Lemonnier, E., Lemonnier, Eric, Christopher Gillberg, Ben-Ari, Y., Hippolyte, L., Åsberg Johnels, Jakob,, Amandine Lassalle   +27 more
core   +2 more sources

Bumetanide for autism spectrum disorder: Current evidence (eng)

Klinik Psikiyatri Dergisi, 2020
-No abstract is available since it is structured as a "Letter to the Editor".
Mazlum Çöpür, Sidar Copur
doaj   +2 more sources

Failure of bumetanide to improve outcome after intracerebral hemorrhage in rat.

PLoS ONE, 2019
After intracerebral hemorrhage (ICH), brain edema commonly occurs and can cause death. Along with edema, there are significant alterations in the concentrations of key ions such as sodium, potassium, and chloride, which are essential to brain function ...
Cassandra M Wilkinson, Brittany A Fedor, Jasmine R Aziz, Colby A Nadeau, Paul S Brar, Julia J A Clark, Frederick Colbourne   +6 more
doaj   +2 more sources